Rasagiline, marketed under the brand name Azilect, is a medication primarily used in the management of Parkinson's disease. It belongs to a class of drugs known as selective, irreversible monoamine oxidase B (MAO-B) inhibitors. Parkinson's disease is a progressive neurodegenerative disorder characterized by motor symptoms such as tremor, rigidity, bradykinesia (slowness of movement), and postural instability, resulting from the degeneration of dopamine-producing neurons in the brain. Rasagiline helps to increase the levels of dopamine in the brain by preventing its breakdown. It can be used alone (monotherapy) in early Parkinson's disease or as an add-on therapy with other Parkinson's medications, such as levodopa, in more advanced stages. The medication is taken orally, typically once daily. (NIH ODS, DrugBank)
Deep dive
Tap a section to expand.
Known interactions
Category rule: supplement × medication
Note
Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).
Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Category rule: vitamin × medication
Note
Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).
Specific pairs are checked against a licensed source; confirm with your provider.
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Compound-pair rule
Avoid
Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.
Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).
Frequently asked
Sources referenced
["Cochrane Library","DrugBank","Examine.com","FDA label (Azilect)","Mayo Clinic","MedlinePlus","National Institutes of Health (NIH) Office of Dietary Supplements (ODS)","PubChem"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the medication category or studied for the same goals.
